Ключевые слова:
Recombinant human erythropoietin; Аnemia of prematurity
antianemic agent; hemoglobin; recombinant erythropoietin; anemia; Apgar score; Article; brain hemorrhage; comparative study; controlled study; drug dose comparison; extremely low birth weight; gestational age; hormonal therapy; hospitalization; human; infant; leukomalacia; lung dysplasia; major clinical study; necrotizing enterocolitis; newborn; prematurity; prevalence; prospective study; respiratory care; retinopathy
Шарафутдинова Д. Р. Дияна Рашидовна 1990-
Балашова Е. Н.
Ионов О. В. Олег Вадимович 1971-
Kirtbaya A. R. Anna Revazievna 1981-
Голубцова Й. М.
Зубков В. В. Виктор Васильевич 1964-
Дегтярев Д. Н. Дмитрий Николаевич 1960-
Павлович С. В. Станислав Владиславович 1968-
Sharafutdinova D. R. Diyana Rashidovna 1990-
Balashova E. N.
Ionov O. V. Oleg Vadimovich 1971-
Киртбая А. Р. Анна Ревазиевна 1981-
Golubtsova J. M.
Zubkov V. V. Viktor Vasilyevich 1964-
Degtyarev D. N. Dmitrij Nikolaevich 1960-
Pavlovich S. V. Stanislav Vladislavovich 1968-
The recombinant human erythropoietin therapy for extremely and very low birth weight infants
Текст визуальный непосредственный
Вопросы гематологии/онкологии и иммунопатологии в педиатрии
Фонд поддержки и развития в области детской гематологии, онкологии и иммунологии Врачи, инновации, наука - детям
Т. 18, Вып. 2 С. 75-82
2019
Статья
Recombinant human erythropoietin Аnemia of prematurity
antianemic agent hemoglobin recombinant erythropoietin anemia Apgar score Article brain hemorrhage comparative study controlled study drug dose comparison extremely low birth weight gestational age hormonal therapy hospitalization human infant leukomalacia lung dysplasia major clinical study necrotizing enterocolitis newborn prematurity prevalence prospective study respiratory care retinopathy
Anemia of prematurity is a common pathology in premature infants. The prevalence of anemia of prematurity is inversely proportional to the gestational age and body weight at birth. The pathogenetic importance of impaired erythropoietin (EPO) production in anemia of prematurity provides the rationale for therapy with erythropoiesis stimulating agents (ESAs) including recombinant EPO. A comparative analysis of the effectiveness of different regimens of recombinant human erythropoietin in extremely and very low birth weight infants (ELBW and VLBW) was studied. Research has been set as a prospective analysis of 133 VLBW and ELBW infants (in the period from December 2017 to February 2019). Gestational age (GA) of the children ranged from 26 to 33 weeks, of these, GA of 75 children (56[%]) was 30 weeks or less. Depending on the treatment of anemia of prematurity all infants were divided into 5 groups: group 1 (n = 26) – premature babies who were prescribed ESAs since 3 day of life 200 IU/kg 3